Compare Eli Lilly And Co (LLY) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs VanEck Vietnam ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while VanEck Vietnam ETF trades at $16.72 (market cap $469.76M). The key difference: Eli Lilly And Co is far larger — about 2213.9× VanEck Vietnam ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while VanEck Vietnam ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and VanEck Vietnam ETF for 51 Days on average.
| LLY | VNM | |
|---|---|---|
Market Cap | $1.04T | $469.76M |
Volume | 3,064,878 | 375,157 |
Sector | Health | Sector/Thematic |
52-Week High | $1.28K | $19.80 |
52-Week Low | $799.57 | $16.34 |
Typical Hold Time | 93 Days | 51 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
VNM trades at $16.72, down 0.89% today, with a bearish technical signal from moving averages but bullish momentum from oscillators. The stock faces sector concentration risks in real estate and financials while benefiting from Vietnam's potential US trade deal progress. Key support and resistance cluster around $17, with RSI levels indicating potential oversold conditions.
The outlook remains cautious due to sector headwinds and interest rate sensitivity, though fair valuation and macroeconomic growth prospects offer long-term potential. Near-term performance depends on trade developments and sector stability, with institutional sentiment mixed on timing and risk exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
